Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Investor Presentation (April 2024)

41 slides from Kazia Therapeutics's investor presentation, April 2024

  1. Slide 1: A Diversified Oncology Drug Development Company

    A Diversified Oncology Drug Development Company Kazia Corporate Overview April 2024 NASDAQ: KZIA | Twitter: @KaziaTx

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar words. Any statement describ

  3. Slide 3: Company Overview

    Company Overview A late-clinical-stage oncology drug development company Paxalisib EVT801 Since delisting from Australian Securities Exchange (ASX) in November 2023, the Company has Brain-penetrant pan-PI3K / mTOR inhibitor Selective VEGFR3 inhibitor been solely listed on NASDAQ (KZIA) • Well-valida

  4. Slide 4: Pipeline – Two Differentiated Assets

    Pipeline – Two Differentiated Assets CY2024 anticipated data releases has the potential to be transformative Paxalisib licensed from: Investigational, small molecule, potent, brain-penetrant inhibitor of PI3K / mTOR Preclinical PHASE 1 PHASE 2 PHASE 3 MARKET Anticipated Glioblastoma & IDH-mutant gli

  5. Slide 5: Paxalisib

    Paxalisib 4

  6. Slide 6: Paxalisib Mechanism of Action

    Paxalisib Mechanism of Action Only brain-penetrant drug in development within the PI3K inhibitor class 1 The PI3K pathway is activated in 2 Five PI3K inhibitors have already 3 Paxalisib is the only brain- many forms of cancer been approved by FDA penetrant PI3K inhibitor • Chronic lymphocytic Only 2

  7. Slide 7: Glioblastoma

    Glioblastoma 6

  8. Slide 8: Paxalisib in Glioblastoma: High unmet need

    Paxalisib in Glioblastoma High unmet need, especially in ‘MGMT unmethylated’ patients Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles Methylated MGMT Status ~35% of patients respond to temoz

  9. Slide 9: Phase II study suggests encouraging PFS and OS

    Paxalisib in Glioblastoma Phase II study suggests encouraging PFS and OS in context of current treatment landscape Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Median PFS: 8.6 months (6.6-11.0) Median OS: 15.7 months (11.1-19.1) Comparator figure for existing therapy: 5.3 mont

  10. Slide 10: Safety profile in Phase II study

    Paxalisib in Glioblastoma Safety profile in Phase II study is favorable for a drug in advanced cancer Number of Patients at Any Dose (n=30) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥10% of patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Fatigue 3 13 2 18 (60%) Stomatitis

  11. Slide 11: GBM-Agile Phase 3 platform study

    Paxalisib in Glioblastoma GBM-Agile: International, multi-center, adaptive, phase 3 study evaluating promising therapeutics in patients with glioblastoma Key Points Completed Regorafenib Negative outcome • A ‘platform study’, sponsored by Bayer (Sep 22) GCAR run independently of individual Paxalisib

  12. Slide 12: GBM AGILE interim analysis may have been premature

    Paxalisib in Glioblastoma We believe GBM AGILE’s interim analysis may have been premature Top line final data anticipated 2Q CY2024 OVERALL STUDY DESIGN up to 150 patients 50 patients Stage 1 (‘Exploratory’) Stage 2 (‘Confirmatory’) Full FDA Approval Blinded Graduation Analysis On August 1, 2022, Pa

  13. Slide 13: Childhood brain cancers

    Childhood brain cancers 12

  14. Slide 14: Paxalisib in Childhood Brain Cancer

    Paxalisib in Childhood Brain Cancer High unmet need especially in patients with diffuse midline gliomas (DMG) 1 Brain cancer is the most common 2 Brain cancer represents about one 3 Prognosis of childhood brain malignancy of childhood third of childhood cancer deaths cancer, especially DMGs, has imp

  15. Slide 15: Summary of Paxalisib in Childhood Brain Cancer

    Summary of Paxalisib in Childhood Brain Cancer Kazia is actively pursuing three forms of childhood brain cancer Diffuse Midline Gliomas Atypical Teratoid / Advanced Childhood Cancer (DMG, DIPG) Rhabdoid Tumors (AT/RT) (PI3K/mTOR activated) Positive preclinical data as Positive preclinical data in mo

  16. Slide 16: Paxalisib in Diffuse Midline Gliomas: Phase I trial

    Paxalisib in Diffuse Midline Gliomas Phase I trial (St. Jude Children study) showed Paxalisib was generally well tolerated in children OVERALL STUDY DESIGN Results from Phase I trial  Maximal Tolerated Dose of paxalisib Newly diagnosed H3K27- Newly-diagnosed DIPG was established mutant DMG  Paxali

  17. Slide 17: PNOC022 multi-arm study and regulatory strategy

    Paxalisib in Diffuse Midline Gliomas Multi-arm, global site study, PNOC022, is underway OVERALL STUDY DESIGN Single agent in target validation Combination therapy in Three different cohorts and/or radiation phase maintenance phase TV: ONC201 Day -1 ONC201 once weekly + Paxalisib Newly-diagnosed DMG

  18. Slide 18: Interim data presented at SNO 2023

    Paxalisib in Diffuse Midline Gliomas Interim data presented at Society of Neuro-Oncology 2023 Annual Meeting in Vancouver, Canada • Sixty-eight patients with biopsy-proven DMG were enrolled between November 2021 and June 2023 (median age 9 years [range 3-37], n=41 female [60%]) • Median OS from time

  19. Slide 19: Case studies from compassionate use

    Paxalisib in Diffuse Midline Gliomas Case studies from compassionate use suggest activity Patient 1 Patient 2 • Commenced Paxalisib + ONC201 immediately • Commenced Paxalisib + ONC201 following following re-irradiation radiotherapy after diagnosis • At 5 months, MRI showed continued regression of •

  20. Slide 20: Brain metastases

    Brain metastases 19

  21. Slide 21: Summary of Brain Metastases Clinical Studies Underway

    Summary of Brain Metastases Clinical Studies Underway Registration Indication Phase N Status Sponsor Secondary (Metastatic) Brain Cancer Brain Metastases NCT04192981 I Up to 36 Recruiting (combination with radiotherapy) Breast Cancer Brain Metastases NCT03765983 II Up to 47 Recruiting (combination w

  22. Slide 22: PI3K pathway mutations in brain metastasis

    Paxalisib in Brain Metastasis PI3K pathway mutations are common in brain metastases and associated with a worse prognosis No Yes PIK3CA mutation Yes No CNS failure after WBRT CNS failure after SRS +PIK3CA mutations at 1 yr –PIK3CA mutations at 1 yr CNS failure after 48 (26-67) 30 (21-40) WBRT, % (95

  23. Slide 23: MSKCC Phase I interim analysis

    Paxalisib in Brain Metastasis MSKCC-sponsored Phase I trial’s interim analysis showed encouraging clinical activity of paxalisib in combination with radiation therapy (NCT04192981) OVERALL STUDY DESIGN 12 patients enrolled (9 evaluable, 3 did not complete protocol treatment) Additional 12 patients S

  24. Slide 24: Brain metastasis interim analysis and Fast Track

    Paxalisib in Brain Metastasis MSKCC-sponsored Phase I trial’s interim analysis showed encouraging clinical activity of paxalisib in combination with radiation therapy (NCT04192981) • August 2022: Data from the first stage was presented at 2022 Annual Conference on CNS Clinical Trials and Brain Metas

  25. Slide 25: Other solid tumors

    Other solid tumors 24

  26. Slide 26: Paxalisib in Metastatic Melanoma

    Paxalisib in Metastatic Melanoma Paxalisib showed potential as therapeutic strategy in refractory melanoma Paxalisib blocked proliferation in vitro (cell confluence assay) Unmet need • Melanoma is the 5th most common cancer for men & women in the U.S. • Approximately 50% of all melanomas harbor an a

  27. Slide 27: Paxalisib in TNBC: QIMR Berghofer collaboration

    Paxalisib in Triple Negative Breast Cancer QIMR Berghofer Medical Institute collaboration • As a leading expert in transcriptional biology and epigenetics, Professor Sudha Rao identified an entirely novel effect of PI3K inhibition – Immune modulator of the tumor and the surrounding microenvironment

  28. Slide 28: TNBC collaboration expected updates

    Paxalisib in Triple Negative Breast Cancer QIMR Berghofer Medical Institute collaboration • The collaboration is nearing completion and anticipate preliminary update in 2Q CY2024 to include: – Combination Paxalisib + KEYTRUDA® (pembrolizumab) data in Triple Negative Breast Cancer preclinical models

  29. Slide 29: Projected TNBC market to exceed $1.4 Billion by 2030

    Paxalisib in Triple Negative Breast Cancer Projected TNBC market to exceed $1.4 Billion by 2030 • Breast cancer is the most commonly diagnosed cancer worldwide, with over 2.3 million new cases each year1 • According to the American Cancer Society, nearly 300,000 new cases of invasive breast cancer a

  30. Slide 30: Paxalisib Licensing and Collaborations

    Paxalisib Licensing and Collaborations Opportunistic partnering and strategic collaborations continue to add value Licensing Key Collaborations • March 2021: Simcere Pharmaceutical Group • QIMR-Berghofer Medical Institute Ltd (Simcere) to develop and commercialize – Cutting edge preclinical program

  31. Slide 31: Paxalisib – Potential Paths to Registration

    Paxalisib – Potential Paths to Registration Multiple opportunities to become a marketed product Diffuse Midline Gliomas Second interim • Potential path to accelerated approval via analysis from ongoing phase II study with ONC201 phase II study • Existing Rare Pediatric Disease Designation creates po

  32. Slide 32: EVT801

    EVT801 31

  33. Slide 33: EVT801 is a highly selective VEGFR3 inhibitor

    EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 • Expected to minimise off-target toxicities Oral Presentation Administered by mouth once or twice daily Strong IP Protection Inhibits lymphangiogene

  34. Slide 34: EVT801 Mechanism of Action

    EVT801 Mechanism of Action By targeting VEGFR3pos tumor blood vessels, EVT801 would induce tumor blood vessels normalization, reduce hypoxia, and improve CD8 T-cells infiltration Schematic overview based on pre-clinical data EVT801 activity on tumor microenvironment Tumor metastasis Normalization of

  35. Slide 35: EVT801 Phase 1 dose-finding trial design

    EVT801: Phase 1 dose-finding trial; KZA 0801-101 (NCT05114668) Staged development in patients with advanced cancer Target population: Histologically-confirmed advanced or metastatic solid tumors, unresponsive to standard treatment, or for whom no standard treatment is available or appropriate STAGE

  36. Slide 36: EVT801 Phase 1 study update

    EVT801: Phase 1 dose-finding trial; KZA 0801-101 (NCT05114668) Staged development in patients with advanced cancer EVT801 Clinical Study Protocol Number Study Name Study Update KZA 0801-101 A Phase 1, First in Human, Open Label Study to To date 32 patients included in the study Assess the Safety, To

  37. Slide 37: VEGFR3 expression in ovarian cancer patients

    EVT801: Phase 1 dose-finding trial; KZA 0801-101 (NCT05114668) Preliminary data from ongoing study demonstrates patients with high grade serous ovarian cancer have moderate to high expression of VEGFR3 Preliminary data from ongoing KZA 0801-101 clinical study EVT801 pre-clinical activity on tumour m

  38. Slide 38: EVT-801 Key Points

    EVT-801 Key Points 1 Well-understood mechanism (anti-angiogenesis) with unique differentiating feature (high VEGFR3 selectivity) 2 Very strong preclinical data package, with evidence of activity in multiple tumours and favourable toxicology 3 Potential for combination use with immuno-oncology therap

  39. Slide 39: 2024 Corporate Focus

    2024 Corporate Focus 38

  40. Slide 40: 2024 Corporate Focus: Objectives for Value Creation

    Kazia Therapeutics: 2024 Corporate Focus Objectives for Value Creation • Complete Paxalisib phase 3 GBM Agile analysis and based on outcome, execute regulatory strategy to prepare for FDA discussions and NDA submission • Execute Paxalisib pediatric and brain metastasis development programs – PNOC022

  41. Slide 41: www.kaziatherapeutics.com

    www.kaziatherapeutics.com info@kaziatherapeutics.com

Kazia Therapeutics — Investor Presentation (April 2024) on 6ix